Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00083213
Recruitment Status : Completed
First Posted : May 19, 2004
Last Update Posted : June 3, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE May 14, 2004
First Posted Date  ICMJE May 19, 2004
Last Update Posted Date June 3, 2016
Study Start Date  ICMJE January 2004
Actual Primary Completion Date May 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE Not Provided
Original Primary Outcome Measures  ICMJE Not Provided
Change History Complete list of historical versions of study NCT00083213 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Official Title  ICMJE An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma
Brief Summary

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Detailed Description

OBJECTIVES:

Primary

  • Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Secondary

  • Determine the maximum tolerated intravenous dose of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.
  • Determine, preliminarily, the ability of this drug to alter tumor blood flow and tumor vascular permeability in these patients.
  • Determine whether antibodies to this drug develop in these patients.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive VEGF Trap IV over 1 hour on days 1 and 15 for a total of 2 doses.

Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level.

In the absence of dose-limiting toxicity, patients with stable disease or partial or complete remission may continue to receive VEGF Trap on a separate extension protocol.

Patients are followed at weeks 1, 3, and 7 and then at 3 months.

PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cancer
Intervention  ICMJE Biological: ziv-aflibercept
Study Arms  ICMJE Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November¬†8,¬†2006)
25
Original Enrollment  ICMJE Not Provided
Study Completion Date  ICMJE Not Provided
Actual Primary Completion Date May 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

DISEASE CHARACTERISTICS:

  • Histologically confirmed diagnosis of one of the following:

    • Non-Hodgkin's lymphoma
    • Primary or metastatic solid tumor located, by radiography, in at least one of the following sites:

      • Liver
      • Soft tissue
      • Pelvis
      • Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field)
  • Relapsed or refractory (including unresectable) disease

    • Patients with solid tumors must have failed all curative chemotherapeutic regimens
    • Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab
  • Not amenable to available conventional therapies AND no standard therapy exists
  • Measurable disease
  • No prior or concurrent CNS metastases (brain or leptomeningeal)
  • No primary intracranial tumor by MRI or CT scan
  • No histologically confirmed squamous cell carcinoma of the lung

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • WBC ≥ 3,500/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 100,000/mm^3
  • No severe or uncontrolled hematologic condition

Hepatic

  • Bilirubin ≤1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN
  • PT and PTT normal
  • INR normal
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative

Renal

  • Creatinine ≤ ULN
  • Urine protein/creatinine ratio ≤ 1
  • No severe or uncontrolled renal condition

Cardiovascular

  • No clinically significant acute electrocardiographic abnormalities
  • LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines
  • No untreated or uncontrolled hypertension

    • No blood pressure > 150/100 mm Hg (despite treatment)
  • No isolated systolic hypertension (i.e., systolic blood pressure > 180 mm Hg on at least 2 determinations [on separate days] within the past 3 months)
  • No New York Heart Association class II - IV heart disease
  • No active coronary artery disease requiring acute medical management
  • No angina requiring acute medical management
  • No congestive heart failure requiring acute medical management
  • No ventricular arrhythmia requiring acute medical management
  • No stroke or transient ischemic event within the past 6 months
  • No prior or concurrent peripheral vascular disease

    • No angiographically or ultrasonographically documented arterial or venous occlusive event
    • No symptomatic claudication
  • No symptomatic orthostatic hypotension
  • No other severe or uncontrolled cardiovascular condition

Pulmonary

  • No severe or uncontrolled pulmonary condition
  • No pulmonary embolism within the past 6 months

Immunologic

  • HIV negative
  • No severe or uncontrolled immunologic condition
  • No active current infection requiring antibiotics
  • No prior hypersensitivity reaction to any recombinant proteins, including VEGF Trap

Other

  • No severe or uncontrolled gastrointestinal or musculoskeletal condition
  • No psychiatric condition or adverse social circumstance that would preclude study participation
  • No other condition that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-barrier contraception during and for 3 months after study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap clinical trial
  • At least 3 weeks since prior immunotherapy and recovered
  • No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)

Chemotherapy

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy

  • No concurrent adrenal corticosteroids except low-dose replacement therapy
  • No concurrent systemic hormonal contraceptive agents

Radiotherapy

  • At least 3 weeks since prior radiotherapy and recovered

Surgery

  • At least 3 weeks since prior major or laparoscopic surgery and recovered
  • More than 6 months since prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events

Other

  • More than 30 days since prior investigational drugs
  • No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or aspirin) other than low-dose (1 mg) warfarin for maintaining patency of venous access devices
  • No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors
  • No other concurrent anticancer investigational agents
  • No other concurrent anticancer therapy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 120 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00083213
Other Study ID Numbers  ICMJE REGENERON-VGFT-ST-0202
MSKCC-03137
CDR0000360856 ( Registry Identifier: PDQ (Physician Data Query) )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Regeneron Pharmaceuticals
Study Sponsor  ICMJE Regeneron Pharmaceuticals
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: William P. Tew, MD Memorial Sloan Kettering Cancer Center
PRS Account Regeneron Pharmaceuticals
Verification Date June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP